Project Grant R21HL173827
Award Date
12/20/24
Completion Date
11/30/26
Dollars Obligated
$194K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Santa Barbara, CA 93106, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The project aims to shed novel insights into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and lead to decreased NAD pools, which play a critical...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $231,552 to the University of California, San Diego (UC San Diego) to investigate how the mechanical properties of cardiac tissue, specifically elasticity and viscosity, modulate the interactions between macrophages and fibroblasts to promote cardiac fibrosis. The research aims to develop an engineered cell culture system to study these biomechanical effects...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $740,037 to the University of California, Los Angeles (UCLA) to investigate the role of cardiac fibroblasts in regulating angiogenesis and vascular formation following myocardial infarction. The research aims to evaluate the function of anti-angiogenic factors like collagen type XVIII expressed by cardiac fibroblasts, as well as determine if the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $159,512 to The Leland Stanford Junior University to investigate strategies for mitigating cardiac fibrosis, a key contributor to dilated cardiomyopathy (DCM). The research aims to validate two candidate compounds identified in a prior drug screen, CGS15943 and AM404, using advanced techniques like 3D cardiac organoids and a mouse DCM...
This $110,959 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the mechanisms driving the transition of lipofibroblasts to myofibroblasts in systemic sclerosis, a rare autoimmune fibrosing disease with high mortality. The research aims to define the role of the genes PER3 and CD36 in regulating the lipofibroblast to myofibroblast transition, which is a key driver...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $785,198 to the Albert Einstein College of Medicine in Bronx, NY to study the role of chaperone-mediated autophagy (CMA) in regulating cardiac fibroblast and myofibroblast function and its impact on heart repair following myocardial infarction. The research aims to investigate how CMA modulates the proteomic profile, phenotype, and function of reparative...
This $203,974 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research project to investigate the effects of normal and diseased extracellular matrix (ECM) on the self-renewal and differentiation of airway basal epithelial cells. The project leverages novel tools developed by the co-PIs, including "inside-out" airway organoids and ECM hydrogels derived from normal and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The primary objectives are to: 1) fully characterize at the atomic level three specific functional domains of the cardiac thin filament linked to the...